Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C44H79NO5 |
| Molecular Weight | 702.1018 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1
InChI
InChIKey=SHKXZIQNFMOPBS-OOMQYRRCSA-N
InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
| Molecular Formula | C44H79NO5 |
| Molecular Weight | 702.1018 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017-11-14 |
|
| Role of Aramchol in steatohepatitis and fibrosis in mice. | 2017-11 |
|
| The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. | 2014-12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01094158
Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:33:24 GMT 2025
by
admin
on
Mon Mar 31 23:33:24 GMT 2025
|
| Record UNII |
QE1Q24M65Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90179395
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
DB11860
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
QE1Q24M65Y
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
12005
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
300000025658
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
18738120
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
246529-22-6
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
Aramchol
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY | |||
|
C188616
Created by
admin on Mon Mar 31 23:33:24 GMT 2025 , Edited by admin on Mon Mar 31 23:33:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->INHIBITOR OF EXPRESSION |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|